Shatavari root extract shows perimenopause benefits: RCT (NutraIngredients)

Tier 2: Professional organization or credentialed expert guidance
Publisher: NutraIngredients (William Reed) · Published: August 26, 2026 · Accessed: August 27, 2026

Visit the source ↗

Claims this source supports

• A randomized, double-blind, placebo-controlled trial in India found that daily supplementation with 300 mg of standardized Shatavari root extract (SRI-81) for eight weeks significantly improved menopausal symptom severity, hot-flash scores, perceived stress, fatigue, and vigor in perimenopausal women compared with placebo.
• The study included 80 perimenopausal women aged 40-55; data from the 73 who completed showed total Menopause Rating Scale scores decreased 42.6% from baseline in the shatavari group versus 5.5% in the placebo group, perceived stress declined almost 30%, and hot-flash scores decreased 26% versus 7%.
• SRI-81 is standardized to Shatavarin IV and total shatavarins and is manufactured by Ixoreal Biomed; the extract is rooted in Ayurvedic tradition and shatavari is reported to contain phytoestrogens, with shatavarins described as potentially interacting with estrogen receptors (mechanism hypothesis, not tested in this trial).
• No adverse events were reported during the trial and liver and kidney function markers remained stable.